4/A//SEC Filing
PURA VIDA INVESTMENTS, LLC 4/A
Accession 0001829126-22-009190
CIK 0001642380other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 4:33 PM ET
Size
30.1 KB
Accession
0001829126-22-009190
Insider Transaction Report
Form 4/AAmended
PURA VIDA INVESTMENTS, LLC
10% Owner
Transactions
- Purchase
Common Stock
2022-04-14$1.33/sh+767,952$1,023,296→ 767,952 total(indirect: By Pura Vida X Fund LP) - Purchase
Common Stock
2022-04-14$1.33/sh+1,665,898$2,219,809→ 7,350,447 total(indirect: By Pura Vida Master Fund, Ltd.) - Purchase
Common Stock
2022-04-14$1.26/sh+92,370$116,386→ 7,473,607 total(indirect: By Pura Vida Master Fund, Ltd.) - Purchase
Common Stock
2022-04-14$1.23/sh+30,790$37,779→ 7,381,237 total(indirect: By Pura Vida Master Fund, Ltd.) - Purchase
Common Stock
2022-04-14$1.33/sh+1,916,419$2,553,628→ 8,455,823 total(indirect: By the Managed Accounts) - Purchase
Common Stock
2022-04-14$1.33/sh+1,381,438$1,840,766→ 1,381,438 total(indirect: By Trust) - Purchase
Warrant to purchase common stock
2022-04-14+832,949→ 832,949 total(indirect: By Pura Vida Master Fund, Ltd.)Exercise: $1.53From: 2022-04-19Exp: 2027-04-19→ Common Stock (832,949 underlying) - Purchase
Warrant to purchase common stock
2022-04-14+383,976→ 383,976 total(indirect: By Pura Vida X Fund LP)Exercise: $1.53From: 2022-04-19Exp: 2027-04-19→ Common Stock (383,976 underlying) - Purchase
Warrant to purchase common stock
2022-04-14+690,719→ 690,719 total(indirect: By Trust)Exercise: $1.53From: 2022-04-19Exp: 2027-04-19→ Common Stock (690,719 underlying) - Purchase
Common Stock
2022-04-14$1.23/sh+19,210$23,571→ 8,475,033 total(indirect: By the Managed Accounts) - Purchase
Common Stock
2022-04-14$1.26/sh+57,630$72,614→ 8,532,663 total(indirect: By the Managed Accounts) - Purchase
Warrant to purchase common stock
2022-04-14+958,209→ 958,209 total(indirect: By the Managed Accounts)Exercise: $1.53From: 2022-04-19Exp: 2027-04-19→ Common Stock (958,209 underlying)
Footnotes (4)
- [F1]Each share of common stock was purchased together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325.
- [F2]Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund"), Pura Vida X Fund LP (the "Pura Vida X Fund"), Lockheed Martin Corporation Master Retirement Trust (the "Retirement Trust"), and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
- [F3]By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
- [F4]The Warrants are subject to an ownership blocker provision that prevents the holder from exercising the Warrants if it would beneficially hold more than 19.99% of the common stock following such exercise.
Documents
Issuer
Oncocyte Corp
CIK 0001642380
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001590144
Filing Metadata
- Form type
- 4/A
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 4:33 PM ET
- Size
- 30.1 KB